



OPEN ACCESS

APPROVED BY

Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Frontiers Production Office
production.office@frontiersin.org

SPECIALTY SECTION

This article was submitted to
Pain Mechanisms and Modulators,
a section of the journal
Frontiers in Molecular Neuroscience

RECEIVED 27 June 2022

ACCEPTED 27 June 2022

PUBLISHED 05 July 2022

CITATION

Frontiers Production Office (2022)
Erratum: Long March Toward Safe and
Effective Analgesia by Enhancing Gene
Expression of *Kcc2*: First Steps Taken.
Front. Mol. Neurosci. 15:979385.
doi: 10.3389/fnmol.2022.979385

COPYRIGHT

© 2022 Frontiers Production Office.
This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](#). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s)
are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Erratum: Long March Toward Safe and Effective Analgesia by Enhancing Gene Expression of *Kcc2*: First Steps Taken

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

pain, spinal cord dorsal horn, *KCC2*, *Kcc2* gene expression enhancer, GSK3, delta-catenin, Kaiso

An Erratum on

Long March Toward Safe and Effective Analgesia by Enhancing Gene Expression of *Kcc2*: First Steps Taken

by Liedtke, W. (2022). *Front. Mol. Neurosci.* 15:865600. doi: 10.3389/fnmol.2022.865600

Due to a production error, the “Conflict of Interest” statement incorrectly stated that “WL was a full-time” instead of “WL is a full-time.”

The corrected section should read:

“WL is a full-time executive employee of Regeneron Pharmaceuticals, Tarrytown, NY, United States.”

The publisher apologizes for this mistake. The original version of this article has been updated.